Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.

MLA

Obara, Wataru, et al. “Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-Wide Expression Profile Analysis for Bladder Cancer.” Japanese Journal of Clinical Oncology, vol. 42, no. 7, July 2012, pp. 591–600. EBSCOhost, https://doi.org/10.1093/jjco/hys069.

APA

Obara, W., Ohsawa, R., Kanehira, M., Takata, R., Tsunoda, T., Yoshida, K., Takeda, K., Katagiri, T., Nakamura, Y., & Fujioka, T. (2012). Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Japanese Journal of Clinical Oncology, 42(7), 591–600. https://doi.org/10.1093/jjco/hys069

Chicago

Obara, Wataru, Ryuji Ohsawa, Mitsugu Kanehira, Ryo Takata, Takuya Tsunoda, Koji Yoshida, Kazuyoshi Takeda, Toyomasa Katagiri, Yusuke Nakamura, and Tomoaki Fujioka. 2012. “Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-Wide Expression Profile Analysis for Bladder Cancer.” Japanese Journal of Clinical Oncology 42 (7): 591–600. doi:10.1093/jjco/hys069.